Addition of sunitinib to cetuximab and irinotecan in patients with heavily pre-treated advanced colorectal cancer

Author： Qvortrup Camilla Jensen Benny Vittrup Jorgensen Trine Lembrecht Nielsen Dorte Bjerregaard Jon Kroll Pfeiffer Per

Publisher： Informa Healthcare

ISSN： 0284-186X

Source： Acta Oncologica, Vol.49, Iss.6, 2010-08, pp. : 833-836

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

AbstractResults of continuous sunitinib, in combination with cetuximab and irinotecan every other week (SIC) for compassionate use in heavily pre-treated patients with mCRC are presented. Patients and methods. Patients with mCRC resistant to oxaliplatin, irinotecan, 5-FU and cetuximab received SIC at two Danish oncologic departments. The regimen consisted of sunitinib given as a continuous-dosing in combination with cetuximab and irinotecan every other week (CetIri). The first six patients started with a daily oral dose of sunitinib of 12.5 mg. Subsequent patients started at a daily dose of 25 mg with the possibility to escalate to 37.5 mg. Results. Twenty-nine patients received SIC. No patient had an objective response, but 13 patients had subjective relief and 42% had stable disease. The median time to progression was 3.2 months and median overall survival was 7.4 months. Fatigue and leukopenia were the most frequently reported severe adverse event (18% grade 3 and 18% grade 3/4, respectively). Discussion. Sunitinib continuous-dosing with 25 mg/day can safely be combined with CetIri administered every other week.